Skip to content

Study · Not a test of the peptide alone · 1985

4 results

The biological relevance of HPLC-purified vasoactive intestinal polypeptide monoiodinated at tyrosine 10 or tyrosine 22.

Marie JC, Hui Bon Hoa D, Jackson R, Hejblum G, Rosselin G

Regulatory peptides1 Oct 1985Cited by 14 (Europe PMC)

PMID2999881 (opens in a new tab)DOI10.1016/0167-0115(85)90192-2 (opens in a new tab)PepBankPUB-02999881
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In HT-29 colonic cells, four monoiodinated VIP species had mean potencies of 0.98, 0.84, 1.38 and 1.48 relative to native VIP for cAMP production.

    In plain wordsIn lab tests on colon cells, four iodinated VIP forms had potencies of 0.98, 0.84, 1.38 and 1.48 relative to native VIP for cAMP production.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicablecAMP stimulation by iodinated VIP species relative to native VIP
    Study

    humann: not reported in source

    HT-29 transformed colonic cells in culture
    Comparator
    Native VIP
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Measurements

    Relative potency peak 1
    0.98 % of native VIP
    M125I-VIP peak 1
    Relative potency peak 2
    0.84 % of native VIP
    M125I-VIP peak 2
    Relative potency peak 3
    1.38 % of native VIP
    M125I-VIP peak 3
    Relative potency peak 4
    1.48 % of native VIP
    M125I-VIP peak 4

    Source sentences

    Summary
    The mean potencies of the M125I-VIP species expressed as a percentage relative to the potency of native VIP were, peak (1): 0.98; (2): 0.84; (3): 1.38; (4): 1.48, in the range of concentrations tested (2-60 pM).
    1 context sentence
    Summary · context
    The ability of the different species of M125I-VIP to stimulate adenosine cyclic 3',5'-phosphate (cAMP) production in transformed colonic cells in culture (HT-29) was compared to that of native VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In HT-29 colonic cells, Tyr22-iodinated VIP was significantly more active than native VIP for cAMP production (P less than 0.01).

    In plain wordsIn lab tests on colon cells, VIP iodinated at position 22 was more active than native VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseActivity of M125I-Tyr22-VIP versus native VIP
    Study

    humann: not reported in source

    HT-29 transformed colonic cells in culture
    Comparator
    Native VIP
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    The M125I-Tyr22-VIP are significantly more active than native VIP (P less than 0.01).
    1 context sentence
    Summary · context
    The ability of the different species of M125I-VIP to stimulate adenosine cyclic 3',5'-phosphate (cAMP) production in transformed colonic cells in culture (HT-29) was compared to that of native VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In HT-29 colonic cells, methionine oxidation or iodination of Tyr10 did not significantly change the biological activity of VIP.

    In plain wordsIn lab tests on colon cells, oxidizing methionine or adding iodine at position 10 did not change VIP activity significantly.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeEffect of methionine oxidation or Tyr10 iodination on VIP activity
    Study

    humann: not reported in source

    HT-29 transformed colonic cells in culture
    Comparator
    Native VIP
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    Oxidation of methionine or iodination of tyrosine 10 does not significantly modify the biological activity of VIP.
    1 context sentence
    Summary · context
    The ability of the different species of M125I-VIP to stimulate adenosine cyclic 3',5'-phosphate (cAMP) production in transformed colonic cells in culture (HT-29) was compared to that of native VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Other

    HPLC separated monoiodinated VIP into peaks: peaks 1 and 2 are iodinated at Tyr10, peak 3 is iodinated at Tyr22, and peaks 1 and 3 have oxidized methionine.

    In plain wordsIn lab tests, iodinated VIP separated into four forms that differ by where the iodine sits and whether methionine is oxidized.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableIdentity of iodinated VIP peaks
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    The first two eluting peaks 1 and 2 are (M125I-Tyr10-VIP); peak 1 has an oxidized methionine; peak 3 is a (M125I-Tyr22-VIP) which also has an oxidized methionine.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.